Description
Corilip Pharmacodynamics
Combined drug, the effect of which is determined by the effects of its constituent vitamins and coenzymes, as well as their synergistic action.
Cocarboxylase (coenzyme) catalyzes carboxylation and decarboxylation of a-keto acids, participates in the processes of carbohydrate metabolism. Through participation in the pentose cycle it indirectly regulates the synthesis of nucleic acids, proteins, and lipids. Helps correct metabolic acidosis and cellular hypoxia, as well as other metabolic disorders (liver, kidney, cardiovascular system, chronic intoxication).
Riboflavin (vitamin B2) as a coenzyme of flavin proteins is involved in the regulation of redox reactions (in the processes of carbohydrate, protein and fat metabolism). It plays an important role in the synthesis of hemoglobin and in maintaining normal visual function of the eye, the condition of mucous membranes and skin.
Thioctic acid is involved in oxidative decarboxylation of pyruvic acid and other a-keto acids, in the regulation of lipid and carbohydrate metabolism, plays an important role in energy production in the body. Thioctic acid has hepatoprotective effect, improves the detoxifying function of the liver, protects against the effects of exo- and endotoxins.
Corylip improves tissue metabolism in various physiological and pathological conditions in need of correction by cofactors and substrates.
Indications
The drug is indicated for use with prophylactic and therapeutic purposes in the treatment of various pathological conditions in children and adults, such as:
– Chronic tissue hypoxia;
– Reduced immunity;
– Bacterial and viral infections, including acute intestinal infections;
– Chronic somatic diseases;
– Chronic intoxications;
– Nutritional disorders (hypotrophy) in children.
Children before admission to children’s institutions, before prophylactic vaccinations.
Adults and children at intense physical and mental stress, in stressful situations, conditions after serious illness.
As a general prophylactic for adults and children during epidemics of infectious diseases.
As a metabolic agent in women in preparation for pregnancy and in the development of feto-placental insufficiency during pregnancy.
Contraindications
Childhood under 1 year of age.
Hypersensitivity reaction to the components included in the drug.
Inflammation or bleeding in the rectum (contraindication related to the route of administration).
Caution:
Not described.
Pregnancy and lactation:
It is possible to use in pregnancy. Should refrain from use during breast-feeding (no clinical data available).
Childhood under 1 year of age.
Hypersensitivity reaction to the components included in the drug.
Inflammation or bleeding in the rectum (contraindication related to the route of administration).
Caution:
Not described.
Pregnancy and lactation:
It is possible to use in pregnancy. Should refrain from use during breast-feeding (no clinical data available).
Directions for use and dosages.
- The drug is used rectally (inserted into the rectum).
- The suppositories are administered to children from 1 to 6 years old – 1 suppository per day, children from 6 to 14 years old – 1-2 suppositories per day, children over 14 years old and adults – 2-3 suppositories per day.
- Duration of treatment for bacterial and viral infections is 6-9 days. In other pathological conditions in children – 10 days, a total duration of treatment – 3 – 4 courses with an interval of 20 days (3-4 months).
- At intense physical and mental stress, stressful situations, conditions after severe diseases, before admission to children’s institutions, before prophylactic vaccinations, during epidemics of infectious diseases duration of treatment is 10 days.
- During pregnancy the duration of treatment is 10 days. The total duration of treatment is 4-5 courses of treatment with intervals of 20 days. Women preparing for pregnancy should use the drug 3 to 6 months before pregnancy, a course of 10 days every 20 days.
